ABL1 and acute myeloid leukemia: This is exemplified by cells carrying point mutations on the BCR-ABL or FLT3-TKD genes, which are de facto resistant to TKI treatment [27, 28], and by resistance to BCL-2 inhibitor venetoclax [29] or to standard chemotherapy [30, 31] in AML.